Everything drug pricing and policy, every day
And a MedPage essay that looks at the danger of naming key health programs after polarizing figures
And Oz weighs in on what comes next for MFN: “We want 95% of all drugs sold in America to be at most favored nation pricing”
And the UK is reportedly reconsidering how much it is willing to pay for medicines
And it’s a big day for IRA lawsuits, with Novo’s suit rejected by an appeals court even as a second court prepares to hear PhRMA make its case
And Colorado’s PDAB moves forward and sets an ‘upper payment limit’ for Enbrel, raising legal and coverage questions
And one last roundup of backstory and commentary on this week’s MFN news
And Gallup says that pharma’s favorability rose 8 percentage points to 28%. Is that worth celebrating?
And as the government shuts down, KFF quantifies the impact of the loss of ACA plan subsidies
Two new pharm-to-table programs highlight different ways of approaching cash-pay markets
